Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Clinical Trials for Hepatobiliary and Pancreatic Cancer Diagnosis and Treatment
share announcement

Clinical Trials for Hepatobiliary and Pancreatic Cancer Diagnosis and Treatment

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 1371

Special Issue Editor

Dr. Takuji Okusaka

E-Mail Website
Guest Editor
Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
Interests: medical oncology; chemotherapy; targeted therapy; immunotherapy

Special Issue Information

Dear Colleagues,

Hepatobiliary and pancreatic cancer remain among the most challenging malignancies to treat. Of all the modalities available for the treatment of hepatobiliary and pancreatic cancer, only a few treatment modalities including resection and ablation therapy offer an opportunity to cure these conditions. However, in the majority of patients with hepatobiliary and pancreatic cancer, the cancer is already at an advanced and unresectable stage at the time of diagnosis. Even among patients with a curable disease, the long-term outcomes remain unsatisfactory, with 5-year survival rates remaining at a dismal around or below 50% owing to the high rate of recurrence even after treatment with a curative intent. Hence, novel clinical studies are needed to improve diagnostic and therapeutic strategies for the next decade.

This Special Issue will discuss the recent and ongoing clinical trials to establish a better diagnostic method to enable the detection of these types of cancer at an earlier stage, establish effective surgical or non-surgical treatments for patients with localized or systemic disease, and improve the quality of life for patients with such life-threatening diseases at any stage. This Special Issue invites researchers to submit reviews as well as original research articles by 31 October 2024.

Dr. Takuji Okusaka
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biliary cancer
  • liver cancer
  • pancreatic cancer
  • clinical trial
  • diagnosis
  • surgery
  • neoadjuvant therapy
  • adjuvant therapy
  • radiotherapy
  • chemotherapy
  • targeted therapy
  • precision medicine
  • immunotherapy
  • biliary and duodenal stent
  • psycho-oncology
  • palliative and supportive care

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 1567 KiB  
Article
Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Metastatic Pancreatic Cancer
by Faithlore P. Gardner, Zev A. Wainberg, Christos Fountzilas, Nathan Bahary, Mark S. Womack, Teresa Macarulla, Ignacio Garrido-Laguna, Patrick M. Peterson, Erkut Borazanci, Melissa Johnson, Matteo Ceccarelli and Uwe Pelzer
Cancers 2024, 16(7), 1323; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers16071323 - 28 Mar 2024
Viewed by 559
Abstract
The efficacy and safety of olaratumab plus nabpaclitaxel and gemcitabine in treatment-naïve participants with metastatic pancreatic ductal adenocarcinoma was evaluated. An initial phase 1b dose-escalation trial was conducted to determine the olaratumab dose for the phase 2 trial, a randomized, double-blind, placebo-controlled trial [...] Read more.
The efficacy and safety of olaratumab plus nabpaclitaxel and gemcitabine in treatment-naïve participants with metastatic pancreatic ductal adenocarcinoma was evaluated. An initial phase 1b dose-escalation trial was conducted to determine the olaratumab dose for the phase 2 trial, a randomized, double-blind, placebo-controlled trial to compare overall survival (OS) in the olaratumab arm vs. placebo arms. In phase 1b, 22 participants received olaratumab at doses of 15 and 20 mg/kg with a fixed dose of nabpaclitaxel and gemcitabine. In phase 2, 159 participants were randomized to receive olaratumab 20 mg/kg in cycle 1 followed by 15 mg/kg in the subsequent cycles (n = 81) or the placebo (n = 78) on days 1, 8, and 15 of a 28-day cycle, plus nabpaclitaxel and gemcitabine. The primary objective of the trial was not met, with a median OS of 9.1 vs. 10.8 months (hazard ratio [HR] = 1.05; 95% confidence interval [CI]: 0.728, 1.527; p = 0.79) and the median progression-free survival (PFS) was 5.5 vs. 6.4 months (HR = 1.19; 95% CI: 0.806, 1.764; p = 0.38), in the olaratumab vs. placebo arms, respectively. The most common treatment-emergent adverse event of any grade across both arms was fatigue. Olaratumab plus chemotherapy failed to improve the OS or PFS in participants with metastatic PDAC. There were no new safety signals. Full article
(This article belongs to the Special Issue Clinical Trials for Hepatobiliary and Pancreatic Cancer Diagnosis and Treatment)
►▼ Show Figures

Figure 1

11 pages, 1332 KiB  
Article
C-Reactive Protein-to-Albumin Ratio to Predict Tolerability of S-1 as an Adjuvant Chemotherapy in Pancreatic Cancer
by Naotake Funamizu, Akimasa Sakamoto, Takahiro Hikida, Chihiro Ito, Mikiya Shine, Yusuke Nishi, Mio Uraoka, Tomoyuki Nagaoka, Masahiko Honjo, Kei Tamura, Katsunori Sakamoto, Kohei Ogawa and Yasutsugu Takada
Cancers 2024, 16(5), 922; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers16050922 - 25 Feb 2024
Viewed by 516
Abstract
Adjuvant chemotherapy (AC) with S-1 after radical surgery for resectable pancreatic cancer (PC) has shown a significant survival advantage over surgery alone. Consequently, ensuring that patients receive a consistent, uninterrupted S-1 regimen is of paramount importance. This study aimed to investigate whether the [...] Read more.
Adjuvant chemotherapy (AC) with S-1 after radical surgery for resectable pancreatic cancer (PC) has shown a significant survival advantage over surgery alone. Consequently, ensuring that patients receive a consistent, uninterrupted S-1 regimen is of paramount importance. This study aimed to investigate whether the C-reactive protein-to-albumin ratio (CAR) could predict S-1 AC completion in PC patients without dropout due to adverse events (AEs). We retrospectively enrolled 95 patients who underwent radical pancreatectomy and S-1 AC for PC between January 2010 and December 2022. A statistical analysis was conducted to explore the correlation of predictive markers with S-1 completion, defined as continuous oral administration for 6 months. Among the 95 enrolled patients, 66 (69.5%) completed S-1, and 29 (30.5%) failed. Receiver operating characteristic curve analysis revealed 0.05 as the optimal CAR threshold to predict S-1 completion. Univariate and multivariate analyses further validated that a CAR ≥ 0.05 was independently correlated with S-1 completion (p < 0.001 and p = 0.006, respectively). Furthermore, a significant association was established between a higher CAR at initiation of oral administration and acceptable recurrence-free and overall survival (p = 0.003 and p < 0.001, respectively). CAR ≥ 0.05 serves as a predictive marker for difficulty in completing S-1 treatment as AC for PC due to AEs. Full article
(This article belongs to the Special Issue Clinical Trials for Hepatobiliary and Pancreatic Cancer Diagnosis and Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop